Normal View Dyslexic View

IMPROVE-AD: Randomized trial for uncomplicated Type B Aortic Dissection

BJSA
BJS Academy
0000-0000
BJS Foundation Limited
London, UK
The IMPROVE-AD study is funded by the National Heart, Lung, and Blood Institute in the US. The study aims to understand how best to treat type B aortic dissection. It will include up to 1,100 patients from 60 hospitals across the United States and Canada. The trial is powered to demonstrate whether upfront thoracic endovascular repair (TEVAR) is superior to the standard of care of Medical Therapy and intervention when needed during follow up over 4 years. The entire study duration is 7 years with a planned completion in 2030.

Related articles


Closing the treatment gap in knee osteoarthritis — the GEKO trial begins

Closing the treatment gap in knee osteoarthritis — the GEKO trial begins

Dr Raman Uberoi, Dr Anjali Shah, Dr Bhavisha Patel, Dr Loretta Davies, Professor Andrew Price, GEKO study group

16 October 2025
THrough knee AMputation’s impact on quality of Life compared to abovE knee ampuTation: THE HAMLET TRIAL

THrough knee AMputation’s impact on quality of Life compared to abovE knee ampuTation: THE HAMLET TRIAL

Sophie James , Sean Pymer , Catherine Arundel, Laura Doherty, Tom Davill, George Smith

20 October 2025
Copied!